Qrativ's Murali Aravamudan on "What's Possible" for AI in Drug Discovery

In this episode, we talk to Murali Aravamudan, Founder and CEO of AI-driven drug discovery startup Qrativ, a joint venture by the Mayo Clinic and biotech/data science firm reference. Murali and I discuss the surge of medical information and data in the medical industry, the role of artificial intelligence in developing drugs for treatments to various diseases, and the future of AI in drug discovery. For more in-depth interviews on the business applications of artificial intelligence, find us online at: www.TechEmergence.com

Release date

Lydbog: 14. oktober 2017